. 2018 Sep 27;21(12):1079–1089. doi: 10.1093/ijnp/pyy085

Table 1.

Inclusion and Exclusion Criteria

Inclusion
Age 18–55 y, inclusive
Primary diagnosis of DSM-5 major depressive disorder or bipolar disorder
Current moderate-to-severe depressive episode
Minimum of 2 failed antidepressant medication trials of adequate dose and duration (at least one trial within the current depressive episode)^a
Quick Inventory of Depressive Symptomatology, Self-Rated, total score >10 at baseline
24-item Hamilton Depression Rating Scale total score >18^b
Exclusion
Other current DSM-5 disorders, with the exception of anxiety disorders and attention deficit disorder
Electroconvulsive therapy within the past 6 months
Lifetime history of DSM-5 cognitive disorder
Body mass index >40
Inadequately-treated hypertension^b
Daily use of angiotensin converting enzyme inhibitor or angiotensin receptor blocker **
Symptomatic coronary artery disease or congestive heart failure^b
History of transient ischemic attack or neurologic signs during the past year^b
History of or susceptibility to malignant hyperthermia^b
Any contraindication to propofol^b
Diabetes requiring insulin^b
Abnormal kidney function^b
Daily use of opioid medication^b
Daily use of benzodiazepine medication
Pregnant or breastfeeding
Psychiatric instability requiring a higher level of care
Incompetent to provide consent

Criteria for propofol participants are listed. Electroconvulsive therapy (ECT) comparison patients were selected based on similar, but not identical, criteria (as noted by ^a and ^b).

^aECT comparison patients were medication-resistant by clinical history, but antidepressant medication trials were not well documented in all cases.

^bCriterion not applied to ECT comparison patients